SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?

Back

HFA Premium Access

SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?

Session: ePosters in myocardial disease 1

Topic: Clinical

Speaker: Doctor L. Pinheiro (Guimaraes, PT)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Doctor Luisa Pinheiro

Hospital Guimaraes, Guimaraes (Portugal)

1 presentation

0 follower

5 more presentations in this session

Therapeutic value of spironolactone in wild-type transthyretin amyloid cardiomyopathy

Speaker: Doctor L. Pinheiro (Guimaraes, PT)

Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.

Speaker: Ms L. Burgos (Buenos Aires, AR)

Improving survival rates of patients with light-chain cardiac amyloidosis in recent years

Speaker: Doctor T. Nabeta (Sagamihara, JP)

Incidence and progression of left ventricular involvement in patients with arrythmogenic cardiomyopathy

Speaker: Doctor A. Diaz Exposito (Malaga, ES)

Left ventricular non compaction in sub-saharan african adults

Speaker: Doctor N. GAYE (Dakar, SN)

Access the full session

ePosters in myocardial disease 1

Speakers: Doctor L. Pinheiro, Doctor L. Pinheiro, Ms L. Burgos, Doctor T. Nabeta, Doctor A. Diaz Exposito...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources